CPMG Inc

Q2 2020 13F Combination Report, Stock Holdings

Signature - Title
John E. Bateman - Chief Operating Officer
Location
Dallas, TX
Holdings as of
June 30, 2020
Value $
$749M
Num holdings
17
Date filed
8/14/2020, 04:09 PM
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q1 2020 - May 15, 2020
Next filing
Q3 2020 - Nov 16, 2020
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2020 Q2 compared to 2020 Q1 by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John E. Bateman Chief Operating Officer Dallas, Texas 8/14/2020

This Form 13F includes only the reportable 3,063,567 Class A shares of Reata Pharmaceuticals, Inc. ("Reata") over which CPMG, Inc. ("CPMG") had investment discretion as of June 30, 2020. This Form 13F does not include the 1,692,857 Class B shares of Reata over which CPMG had investment discretion as of June 30, 2020 because such Class B shares were not included in the relevant quarter's Official List of Section 13(f) Securities, and thus should be excluded.